1442-9071/asset/CEO_left.gif?v=1&s=5e5fc4bd685babcd879209bdb346065caac754b6)
Mitomycin-C as adjuvant therapy in the treatment of sebaceous gland carcinoma in high-risk locations
Article first published online: 6 APR 2009
DOI: 10.1111/j.1442-9071.2009.02048.x
© 2009 The Authors. Journal compilation © 2009 Royal Australian and New Zealand College of Ophthalmologists
Additional Information
How to Cite
Rudkin, A. K. and Muecke, J. S. (2009), Mitomycin-C as adjuvant therapy in the treatment of sebaceous gland carcinoma in high-risk locations. Clinical & Experimental Ophthalmology, 37: 352–356. doi: 10.1111/j.1442-9071.2009.02048.x
Publication History
- Issue published online: 30 JUN 2009
- Article first published online: 6 APR 2009
- Received 17 December 2008; accepted 19 March 2009.
- Abstract
- Article
- References
- Cited By
Keywords:
- adjuvant;
- chemotherapy;
- mitomycin;
- recurrence;
- sebaceous gland carcinoma
Abstract
Purpose: To report on the use of Mitomycin-C as adjuvant therapy to excision and cryotherapy in patients with sebaceous gland carcinoma (SGC) in high-risk locations.
Design: Retrospective, consecutive, case series.
Participants: Three patients with SGC of the upper palpebral conjunctiva or caruncle, but without clinical pagetoid spread.
Methods: Following excision and double freeze-thaw cryotherapy, patients with histology demonstrating SGC of the ocular surface were treated with topical Mitomycin-C (0.04%). Follow-up was conducted over an average of 30 months (range: 24–37 months).
Main outcome measures: Postoperative evidence of local recurrence, lymph node or distant organ metastasis.
Results: No patients had evidence of local recurrence or systemic disease.
Conclusions: Wide surgical excision with cryotherapy is the basis of treatment of SGC without pagetoid spread. The use of Mitomycin-C as adjuvant therapy remains controversial, although there is some rationale for its use in high-risk situations.